SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001725160-22-000141
Filing Date
2022-08-01
Accepted
2022-08-01 17:22:25
Documents
4
Period of Report
2022-08-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_165938892838565.html 3  
1 FORM 3 wf-form3_165938892838565.xml 3 1714
2 POWER OF ATTORNEY FOR ANDREA PAUL zntl-powerofattorneyxa.htm EX-24 5143
3 POWER OF ATTORNEY FOR ANDREA PAUL P1 zntl-powerofattorneyxa001.jpg GRAPHIC 195418
4 POWER OF ATTORNEY FOR ANDREA PAUL P2 zntl-powerofattorneyxa002.jpg GRAPHIC 82825
  Complete submission text file 0001725160-22-000141.txt   391887
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 65 HAYDEN AVENUE 2ND FLOOR LEXINGTON MA 02421
Business Address
Paul Andrea (Reporting) CIK: 0001863130 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39263 | Film No.: 221125907